Introduction:
We aim to create and compare two digital-health pipelines for voice recording and speech analyses based on smartphones and professional equipment. We benchmark smartphone recording quality on speech features previously shown predictive of neurological impairment.
Methods:
A mobile app records users performing three speech tasks on the built-in microphone while simultaneously recording with professional equipment. Speech features are compared across each recording pair. Tasks include text reading, 20-second syllable repetition, and vowel sustainment. Bland-Altman visualization, Deming regression, correlation tests (Spearman, Intraclass) and Kolmogorov-Smirnov tests were utilized to assess concordance degree across devices.
Dot plots and standard deviation were used to assess longitudinal stability. Signal-to-Noise ratios (inter-speaker feature differences divided by within-speaker feature differences) were utilized to assess across-device reproducibility. Temporal stability was evaluated via relative size differences between speakers, measurement error, and test-retest reproducibility.
Results and Discussion:
20 recording sessions were collected from 3 speakers, with one speaker recording 6 sessions spanning 5 months to explore longitudinal stability. Twenty-three speech features served as a basis for assessing concordance between recording pairs. 19/23 (80%) features were found to be significantly correlated across recording methods; concordance is dependent on feature family. Furthermore, the smartphone’s audio enhancement seems to be affecting some features. While most features (14/23, 63%) seem to be longitudinally unstable, this finding is preliminary as it is based on a single speaker.
Conclusions:
A smartphone-based voice recording and speech analyses pipeline appears potentially feasible, however inter-device variability and possible audio enhancing algorithms deployed in smartphones need to be handled with care. The study is constrained by its very small sample size, therefore much-larger-N Case-Control studies are needed to validate and extend these preliminary findings to clinical settings and across specific neurological disease states.